Resources

As we bid a fond farewell to Christiane Abouzeid after over 20 years of outstanding service to the BioIndustry Association, we are also thrilled to announce new leadership changes within our Policy and Public Affairs team.

£20 million Series A financing underway to support development of lead product

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, will share the BIA’s perspective on the recent Engineering biology public trust survey findings conducted by the Department for Science, Innovation and Technology’s (DSIT).

New St John’s innovation centre strengthens support for technology and life sciences sectors.

The International R&D Tax Guide is a comprehensive resource designed to assist businesses in understanding and leveraging R&D tax incentives across various jurisdictions.

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

Matthew has over 25 years’ experience in drug discovery and development across multiple target classes covering oncology, immunology, neurology, ophthalmology and metabolic disease. He joins from Storm Therapeutics — where he was Senior Vice President of Therapeutics.

Nxera Pharma reports significant progress on its partnered muscarinic agonist portfolio with Neurocrine Biosciences, including plans for Phase 3 schizophrenia trials and multiple Phase 2 studies in 2025.

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $14.6 billion, adding its innovative schizophrenia and bipolar treatment CAPLYTA® to J&J's neuroscience portfolio, along with a promising pipeline of therapies.

A new biotech venture is advancing best-in-class oral and injectable therapies for obesity and cardiometabolic disorders, backed by $411 million in funding from leading global investors.

GSK has announced the acquisition of IDRX-42, a next-generation KIT tyrosine kinase inhibitor (TKI). This $1.15 billion deal strengthens GSK’s portfolio in gastrointestinal cancers.

‘Gastronomica’ is the brainchild of Pioneer Group, which specialises in life science infrastructure and venture-building. The incubator is being created through a cooperation between Pioneer and Unilever.

Medicines Discovery Catapult (MDC), a national Life Sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its Executive team with the appointment of a Chief Commercial Officer and its first Managing Director.

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

Techbio pioneer Etcembly is soft-launching their new immune engineering platform, EMLy™ Copilot, during the 43rd annual JPM Healthcare Conference.

hVIVO plc announces that it has successfully completed a pilot characterisation study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept for a future hVIVO hMPV challenge model to test new vaccines and antivirals.

Cancer Research Horizons opens nominations for its Innovation and Entrepreneurship Awards 2025, which celebrate the UK’s most enterprising efforts in oncology.

Oxford Drug Design, the AI drug discovery company, has successfully completed additional in vivo validation in its potential first-in-class approach against multiple tumours.

Plexāā, a London-based medical device startup, is thrilled to announce a new partnership with Panasonic Manufacturing UK as their contract manufacturer for the award-winning BLOOM⁴³ medical device.